LINC00320: A Potential Drug Target for Neurodegenerative Diseases

Target Name: LINC00320

NCBI ID: G387486

LINC00320

Other Name(s): PRED14 | C21orf131 | NCRNA00320 | long intergenic non-protein coding RNA 320 | Long intergenic non-protein coding RNA 320, transcript variant 4

LINC00320: A Potential Drug Target for Neurodegenerative Diseases

LINC00320 (PRED14) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a key regulator of cell growth and differentiation, and has been identified as a potential drug target for a variety of diseases.

The protein encoded by LINC00320 is composed of secondary structure of 21 kDa伪-helix and 21 kDa尾-helix. The 伪-helix of LINC00320 consists of 11 伪-helical units, of which 4 are at the N-terminus, 3 at the C-terminus, and 3 at the 尾-terminus. The 尾-helix consists of 6 尾-helix units, which are located inside the 伪-helix.

LINC00320's function in cells is being intensively studied. Research shows that LINC00320 plays a key role in neuronal differentiation and synapse formation. Loss of LINC00320 leads to neuronal apoptosis and may also play a role in tumorigenesis.

In addition, LINC00320 also plays an important role in cardiovascular diseases. Studies have shown that LINC00320 is associated with heart disease and diabetes, and may be involved in neurodegenerative diseases.

LINC00320 is also used as a target for therapeutic drugs. Currently, LINC00320 is used in combination with anti-neurodegenerative drugs, a type of drug that treats neurodegenerative diseases, to treat conditions such as Parkinson's disease and Alzheimer's disease.

In conclusion, LINC00320 is a promising drug target for the treatment of multiple neurodegenerative diseases.

Protein Name: Long Intergenic Non-protein Coding RNA 320

The "LINC00320 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC00320 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets